IRCT20220928056051N1已完成3 期
Comparing the effect of Empagliflozin with Pioglitazone on nonalcoholic fatty liver in diabetic type 2 patients treated with metformin
Oroumia University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 75 years（—）
- 性别
- All
入选标准
- •Age between 20 to 75 years
- •Type 2 diabetes
- •A hemoglobin A1C (HbA1c) between 7 and 10
- •Body mass index (BMI) between 20 to 40 kg/m2
- •Treated with metformin for at least three months with a minimum dose of 1500 mg daily
- •?At least grade 1 of non-alcoholic fatty liver disease (NAFLD)
排除标准
- •Patients receiving drugs that stimulate insulin secretion, or insulin
- •Type 1 diabetes
- •Patients treated with diabetes drugs including sitagliptin and liraglutide
- •Glomerular Filtration Rate (GFR) less than 30
- •Uncontrolled or aggravated heart disease (class 3 and 4)
- •Liver diseases including autoimmune hepatitis and viral hepatitis
- •Alcohol consumption of more than 140 cc for women and 250 cc for men per week
- •breastfeeding
- •History of recurrent urinary tract infection
- •Bladder Cancer
研究者
相似试验
已完成
2 期
The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patientsIRCT20190122042450N3Iran University of Medical Sciences105
尚未招募
2 期
Comparing the effect of Empagliflozin, Pioglitazone and their combination, on the course of non-alcoholic fatty liver disease in diabetic patientson-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20230903059343N1Arak University of Medical Sciences120
招募中
2 期
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesK75.81CardiomyopathyIRCT20190122042450N5Iran University of Medical Sciences70
尚未招募
2 期
The effect of Empagliflozin on nonalcoholic fatty liver disease in non-diabetic patientson alcoholic fatty liver disease.Nonalcoholic steatohepatitis [NASH]K75.81IRCT20190122042450N1Iran University of Medical Sciences100
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90